Maze Therapeutics, Inc. (MAZE)

Market Cap	1.58B +218.6%
Revenue (ttm)	n/a
Net Income	-131.12M
EPS	-3.05
Shares Out	49.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,717,107
Open	31.11
Previous Close	31.73
Day's Range	30.16 - 35.28
52-Week Range	6.71 - 53.65
Beta	n/a
Analysts	Strong Buy
Price Target	66.13 (+108.55%)
Earnings Date	Mar 25, 2026

About MAZE

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also deve...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2025
• Employees: 125
• Stock Exchange: NASDAQ
• Ticker Symbol: MAZE
• Website: https://www.mazetx.com

Analyst Summary

According to 8 analysts, the average rating for MAZE stock is "Strong Buy." The 12-month stock price target is $66.13, which is an increase of 108.55% from the latest price.

Price Target

$66.13

(108.55% upside)

Analyst Consensus: Strong Buy